Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Gain Therapeutics Inc GANX

Healthcare Biotechnology
Gain Therapeutics, Inc. is a biotechnology company. The Company is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company’s drug... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:GANX)

Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update

GlobeNewswire 11 hours ago

Gain Therapeutics to Present at Neuroscience 2025

GlobeNewswire 13 days ago

Gain Therapeutics to Attend the 2025 Maxim Growth Summit

GlobeNewswire October 16, 2025

Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease

GlobeNewswire October 9, 2025

Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson's Patients at International Congress of Parkinson's Disease and Movement Disorders® 

GlobeNewswire October 6, 2025

Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025

GlobeNewswire September 23, 2025

Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson's Disease

GlobeNewswire September 18, 2025

Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation

GlobeNewswire September 4, 2025

Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update

GlobeNewswire August 12, 2025
View More News ››

Opinion & Analysis (NDAQ:GANX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:GANX)

New year update from GANX ceo!

https://youtu.be/S3rGQQxSzq0?si=lH0Q0ZZo8-PupT60
BryceCanada - January 11, 2024

New video discussing clinical trials!

https://youtu.be/XEfhw9LCOQY?si=m7PVyM7QqLfStwJq
BryceCanada - October 12, 2023

Excellent interview from Gain CEO

https://youtu.be/dpoZqf702Bs?si=5DePuhTniqTiYMLH
BryceCanada - September 7, 2023
View more Bullboard ››

Sparta Capital Ltd.

Sparta Capital Ltd.

Sparta Capital Ltd. is a technology-based company focused on integrating emerging technologies. It operates with a ...
View More »